Non-small cell lung cancer LYNPARZA® (MK-7339) 1, 2
blue
Head & neck squamous cell carcinoma LENVIMA® (MK-7902) 1, 2
blue
Non-small cell lung cancer LENVIMA® (MK-7902) 1, 2
blue
Melanoma cancer LENVIMA® (MK-7902) 1, 2
blue
Liver LENVIMA® (MK-7902) 1, 2
blue
Endometrial cancer LENVIMA® (MK-7902) 1, 2 (EU)
blue
Bladder cancer LENVIMA® (MK – 7902) 1, 2
blue
Prostate cancer KEYTRUDA® (MK-3475)
blue
Esophageal Cancer KEYTRUDA® (MK-3475) (EU)
blue
Nasopharyngeal cancer KEYTRUDA® (MK-3475)
blue
Mesothelioma cancer KEYTRUDA® (MK-3475)
blue
Biliary tract cancer KEYTRUDA® (MK-3475)
blue
Small cell lung cancer KEYTRUDA® (MK-3475) (EU)
blue
Liver cancer KEYTRUDA® (MK-3475) (EU)
blue
Gastric cancer KEYTRUDA® (MK-3475) (EU)
blue
Endometrial cancer KEYTRUDA® (MK-3475) (EU)
blue
Cutaneous squamous cell carcinoma KEYTRUDA® (MK-3475) (EU)
blue
Cervical cancer KEYTRUDA® (MK-3475) (EU)
blue
Breast cancer KEYTRUDA® (MK-3475) (EU)
blue
Cancer RCC MK-6482
blue
Cough gefapixant (MK-7264)
cyan
Pneumoconjugate vaccine V114
Pneumoconjugate Vaccine V114
V114 is an investigational vaccine currently being evaluated for its ability to provide protection against pneumococcal disease caused by serotypes contained in the vaccine.
For further information on clinical trials, please refer to:
Vericiguat (MK-1242) is an investigational stimulator of soluble guanylate cyclase (sGC) currently being evaluated in a Phase 2b clinical trial of Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure
Phase 1 clinical trials test the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always. The trial often takes place in a hospital. The goals are to determine:
If the medicine or vaccine is safe
If there are any side effects
How the medicine is broken down by and discharged from the body
How much medicine is needed and how often
For a vaccine, researchers see if it causes the desired response from the body’s immune system
Phase 1 trials an take from six months to one year to complete.
Phase 2
Phase 2 clinical trials test the vaccine or medicine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy. The goals of this phase are to determine:
How well the medicine or vaccine works
If the medicine or vaccine is safe
If there are any side effects
How much of the medicine or vaccine is needed and how often
Phase 2 trials can take from six months to one year or more to complete.
Phase 3
Phase 3 clinical trials can test the medicine or vaccine in 1,000 to 5,000 patient volunteers. For medicines, volunteers have the disease or condition the medicine is designed to treat. In vaccine studies, the volunteers may be healthy or have diseases or conditions. Phase 3 trials take place in hospitals, clinics or physician offices. Researchers closely monitor patients at regular intervals to:
Confirm that the medication or vaccine is effective
Identify and monitor side effects
Compare the medicine or vaccine to commonly used treatments
Phase 3 trials can take from one to four years to complete, depending on the disease, length of study and number of volunteers.
Under review
The application has been submitted to the regulatory authorities for review.
No Duty to Update
The information contained in this chart was current as of July 31, 2020. While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after July 31, 2020.
The chart reflects the company research pipeline as of July 31, 2020.
Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.
